Breye Therapeutics

Executive Summary

Breye Therapeutics is a clinical-stage biopharmaceutical company based in Copenhagen, Denmark, founded in 2020. The company focuses on developing novel, orally administered small molecule drugs for major retinal vascular diseases, including diabetic retinopathy (DR) and age-related macular degeneration (AMD). These conditions represent a significant unmet medical need, with millions of patients at risk of vision loss. Current standard-of-care treatments, such as intravitreal injections, are burdensome and often lead to poor compliance. Breye's oral small molecule approach aims to provide a more convenient and effective alternative, potentially improving patient outcomes. The company's lead program is in Phase 1 clinical development, targeting the underlying pathophysiology of retinal vascular disease. As a private company, Breye has not disclosed its total funding, but its innovative approach addresses a large market opportunity, though it remains early-stage with inherent development risks. The company's scientific focus on oral bioavailability and retinal targeting differentiates it from competitors in the ophthalmology space.

Upcoming Catalysts (preview)

• H2 2026Phase 1 interim safety and tolerability data50% success
• 2026Series A funding round completion60% success
• H1 2027Phase 1 proof-of-concept biomarker data40% success